Colestipol Hydrochloride Suspension

Colestipol Hydrochloride Suspension

Colestipol Hydrochloride Suspension Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

TO AVOID ACCIDENTAL INHALATION OR ESOPHAGEAL DISTRESS, COLESTIPOL hydrochloride FOR ORAL SUSPENSION SHOULD NOT BE TAKEN IN ITS DRY FORM. ALWAYS MIX COLESTIPOL hydrochloride FOR ORAL SUSPENSION WITH WATER OR OTHER FLUIDS BEFORE INGESTING.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use.

Colestipol hydrochloride for oral suspension, USP is indicated as adjunctive therapy to diet for the reduction of elevated serum total and low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia (elevated low density lipoproteins [LDL] cholesterol) who do not respond adequately to diet. Generally, colestipol hydrochloride for oral suspension, USP has no clinically significant effect on serum triglycerides, but with its use triglyceride levels may be raised in some patients.

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD.

According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below.

LDL-Cholesterol
mg/dL (mmol/L)
Definite Atheroschlerotic Disease* Two or More Other Risk Factors† Initiation Level Goal
*
Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease).
Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L).
No No ≥190
(≥4.9)
<160
(<4.1)
No Yes ≥160
(≥4.1)
<130
(<3.4)
Yes Yes or No ≥130
(≥3.4)
≤100
(≤2.6)

History

There is currently no drug history available for this drug.

Other Information

Colestipol hydrochloride for oral suspension, USP contains colestipol hydrochloride, which is a lipid lowering agent for oral use. Colestipol hydrochloride is an insoluble, high molecular weight basic anion-exchange copolymer of diethylenetriamine and 1-chloro-2, 3-epoxypropane, with approximately 1 out of 5 amine nitrogens protonated (chloride form). It is a light yellow water-insoluble resin which is hygroscopic and swells when suspended in water or aqueous fluids.

Colestipol hydrochloride for oral suspension, USP is tasteless and odorless. The inactive ingredient is silicon dioxide. One dose (1 packet or 1 level scoopful) of colestipol hydrochloride for oral suspension, USP contains 5 grams of colestipol hydrochloride.

Colestipol Hydrochloride Suspension Manufacturers


  • Global Pharmaceuticals, Division Of Impax Laboratories Inc.
    Colestipol Hydrochloride Suspension [Global Pharmaceuticals, Division Of Impax Laboratories Inc.]

Login To Your Free Account